Aberdeen Group plc cut its stake in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 45.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 474,953 shares of the company’s stock after selling 401,505 shares during the period. Aberdeen Group plc owned 0.24% of WAVE Life Sciences worth $1,757,000 as of its most recent filing with the SEC.
Other hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC raised its holdings in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after purchasing an additional 1,029,052 shares in the last quarter. Renaissance Technologies LLC lifted its position in WAVE Life Sciences by 152.6% in the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock valued at $4,330,000 after purchasing an additional 360,800 shares during the period. Readystate Asset Management LP acquired a new stake in WAVE Life Sciences in the second quarter valued at about $27,465,000. Gabelli Funds LLC purchased a new stake in WAVE Life Sciences in the 1st quarter valued at approximately $127,000. Finally, Sei Investments Co. boosted its holdings in WAVE Life Sciences by 47.2% in the 1st quarter. Sei Investments Co. now owns 80,161 shares of the company’s stock valued at $581,000 after purchasing an additional 25,704 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the company. Wall Street Zen raised WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a report on Saturday, October 31st. Mizuho decreased their target price on shares of WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. William Blair initiated coverage on shares of WAVE Life Sciences in a research note on Friday, October 16th. They set an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of WAVE Life Sciences in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. assumed coverage on shares of WAVE Life Sciences in a report on Wednesday, September 23rd. They issued a “neutral” rating for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.44.
Read Our Latest Stock Analysis on WAVE Life Sciences
WAVE Life Sciences Stock Performance
Shares of NASDAQ WVE opened at $2.56 on Friday. WAVE Life Sciences Ltd. has a 1 year low of $2.55 and a 1 year high of $21.73. The firm’s 50 day moving average price is $3.53 and its 200 day moving average price is $6.71.
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. WAVE Life Sciences had a negative return on equity of 44.66% and a negative net margin of 296.86%. The company had revenue of $13.16 million during the quarter, compared to the consensus estimate of $4.51 million. On average, equities research analysts forecast that WAVE Life Sciences Ltd. will post -1.08 earnings per share for the current fiscal year.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.
Further Reading
- Five stocks we like better than WAVE Life Sciences
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE – Free Report).
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
